Global /China /Healthcare /Drug Manufacturers - General /605116
chevron_leftBack
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd.

605116
SSE: 605116 Delayed
22.60CNY -1.7%
3.34 USD
As of 15 June 2026, Aurisco Pharmaceutical Co.,Ltd. has a market cap of $1.37B USD, ranking #8946 globally and #2366 in China. It ranks #757 in the Healthcare sector, and #283 in the Drug Manufacturers - General industry.
Global Rank
8946
Country Rank
2366
Sector Rank
757
Industry Rank
283
Key Stats
Market Cap
$1.37BUSD
9.28B CNY
Enterprise Value
$1.38BUSD
9.36B CNY
Revenue (TTM)
$248.95MUSD
1.68B CNY
EBITDA (TTM)
$89.77MUSD
607.49M CNY
Net Income (TTM)
$58.18MUSD
393.72M CNY
EBITDA Margin
36%
Profit Margin
23%
PE Ratio
23.9
Forward PE
16.9
PS Ratio
5.5
PB Ratio
3.4
EV/EBITDA
15.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Dingjun Chu open_in_new
Employees
1,784
Founded
1998
Website
aurisco.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-1.7% -14% -15% -21% 0.1% 7.8%

News

Loading...

Markets

Exchange Ticker Price
Shanghai Stock Exchange
MIC: XSHG
PRIMARY
605116
奥锐特药业股份有限公司 Class A
ISIN: CNE1000042S4
Shares Out.:
403.556M1 Shares Float: 64.705M2
TV:
SA:
YF:
GF:
BA:
MS:
22.60 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Aurisco Pharmaceutical Co.,Ltd.

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, and chronic obstructive pulmonary disease; eplerenone preparations are used for the treatment of hypertension and heart failure; bepedalic acid preparations are used for the treatment of hypercholesterolemia or atherosclerotic cardiovascular diseases; tenofovir used for the treatment of HIV-1 infection and chronic hepatitis B; pregabalin preparations are used to treat neuropathic pain, fibromyalgia, epilepsy, etc.; brivaracetam preparations are used to treat epilepsy; abiraterone acetate and enzalutamide preparation preparations for the treatment of prostate cancer; and dydrogesterone preparations are used to treat dysmenorrhea, endometriosis, irregular menstrual cycle, etc. Aurisco Pharmaceutical Co.,Ltd. was founded in 1998 and is headquartered in Tiantai, China.

Similar Companies

Industry: Drug Manufacturers - General (China)
Name
Market Cap diff.
PE
$53.92B
364.89B CNY
4K%
44.9
603259
$49.7B
336.36B CNY
4K%
17.2
$28.52B
223.48B HKD
2K%
35.7
$18.8B
147.32B HKD
1K%
162.3
$16.53B
111.89B CNY
1K%
-
9926
$16.01B
125.46B HKD
1K%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
55K%
38.1
JNJ
$547.28B
40K%
26.4
ABBV
$360.63B
26K%
97.4
$321.52B
256.25B CHF
23K%
19.9
AZN
$288.84B
215.59B GBP
21K%
27.6
NOVN
$274.65B
218.9B CHF
20K%
20.5
chevron_leftBack